Drug efficiency: A new concept to guide lead optimization programs towards the selection of better clinical candidates

Expert Opinion on Drug Discovery

Volumn 5, Issue 7, 2010, Pages 609-618

  Braggio, Simone ^a   Montanari, Dino ^a   Rossi, Tino ^a   Ratti, Emiliangelo ^a  

^a GSK   (Italy)

Author keywords

ADMET; Biophase; CNS; Developability; Drug discovery; Ligand efficiency; Pharmacodynamics; Pharmacokinetics; Physicochemical properties; Volume of distribution

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ATOMOXETINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DIAZEPAM; DOXEPIN; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MAPROTILINE; MESORIDAZINE; MIDAZOLAM; OLANZAPINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; RIZATRIPTAN; SELEGILINE; SERTRALINE; SUMATRIPTAN; TEMAZEPAM; THIORIDAZINE; TIOTIXENE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AGRANULOCYTOSIS; ANOREXIA NERVOSA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HICCUP; HUMAN; INSOMNIA; MAJOR DEPRESSION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE;

EID: 77953693716     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.490553     Document Type: Review

References (19)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
2. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004;1:337-341
3. Leeson PD, Davis AM, Steele J. Drug-like properties: guiding principles for design - or chemical prejudice? Drug Discov Today 2004;1:189-195
4. Lajiness MS, Vieth M, Erickson J. Molecular properties that influence oral drug-like behaviour. Curr Opin Drug Discov Dev 2004;7:470-477
5. Hann, MM, Oprea TI. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004;8:255-263
6. Gleeson MP. Generation of a Set of Simple, interpretable ADMET rules of thumb. J Med Chem 2008;51:817-834
7. Wenlock MC, Austin RP, Barton P, et al. A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 2003;46:1250-1256
8. Hopkins AL. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-431
9. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-890
10. Keserü G, Makara G. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-212
11. Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-4875
12. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug. Discov J Chem Inf Comput Sci 2001;41:856-864
13. Teague SJ, Davis AM, Leeson PD, Oprea T. The design of lead like combinatorial libraries. Angew Chem Int Ed 1999;38:3743-3748
14. Li D, Kerns EH. Application of pharmaceutical profiling assays for optimization of druglike properties. Curr Opin Drug Discov Dev 2005;8:495-504
15. Smith DA, Schmid EF. Drug withdrawals and the lessons within. Curr Opin Drug Discov Dev 2006;9(1):38-46
16. de Lange EC, Danhof M. Considerations in the use of CSF pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703
17. Highlights from the Society for Medicines Research symposium held in London on December 2, 1999. Drug News Perspect 1999;12(10):647-652
18. DRUGDEX: Drug and Pharmaceutical Information, Thomson Reuters Copyright© all rights reserved; 2009
19. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at Human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 Partial Agonist. J Pharmacol Exp Ther 2005;315:1278-1287